Spironolactone improves angiotensin-induced vascular changes and oxidative stress

Hypertension

Volumn 40, Issue 4, 2002, Pages 504-510

  Virdis, Agostino ^a   Neves, Mario Fritsch ^a   Amiri, Farhad ^a   Viel, Emilie ^a   Touyz, Rhian M ^a   Schiffrin, Ernesto L ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Aldosterone; Angiotensin II; Endothelium; Hypertension, arterial; Oxidative stress; Rats; Remodeling

Indexed keywords

ACETYLCHOLINE; ALDOSTERONE; ANGIOTENSIN; HYDRALAZINE; NITROPRUSSIDE SODIUM; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SPIRONOLACTONE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL MODEL; ANIMAL TISSUE; ARTERY MEDIA; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HEART BLOOD VESSEL; HEART MUSCLE RELAXATION; HYPERTENSION; MALE; MESENTERIC ARTERY; MYOGRAPHY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; STIMULUS RESPONSE; SYSTOLIC BLOOD PRESSURE;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II; ANIMALS; ARTERIES; BLOOD PRESSURE; CULTURE TECHNIQUES; ENDOTHELIUM, VASCULAR; HEART; MALE; MESENTERIC ARTERIES; NADPH OXIDASE; ORGAN SIZE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ALDOSTERONE; RENIN; SPIRONOLACTONE; SUPEROXIDES; THIOBARBITURIC ACID REACTIVE SUBSTANCES; VASCULAR RESISTANCE;

EID: 0036791717     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000034738.79310.06     Document Type: Article

References (41)

1. Mulvany MJ, Aalkjaer C. Structure and function of small arteries. Physiol Rev. 1990;70:921-971.
2. Schiffrin EL. Reactivity of small blood vessels in hypertension: relation with structural changes. Hypertension. 1992;19(suppl II):II-1-II-9.
3. Mulvany MJ, Baumbach GL, Aalkjaer C, Heagerty AM, Korsgaard N, Schiffrin EL, Heistad DD. Vascular remodeling. Hypertension. 1996;28:505-506.
4. Lüscher TF, Vanhoutte PM. The Endothelium: Modulator of Cardiovascular Function. Boca Raton, Fla: CRC Press Inc; 1990:1-215.
5. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase. Role of cardiovascular biology and disease. Circ Res. 2000;86:494-501.
6. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-844.
7. Touyz RM. Oxidative stress and vascular damage in hypertension. Curr Hypertens Rep. 2000;1:98-105.
8. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev. 2000;52:639-672.
9. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Theodore Cooper Memorial Lecture. Hypertension. 2001;37:1047-1052.
10. Rajagopalan S, Kurz S, Múnzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
11. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, Heitzer T, Stasch JP, Griendling KK, Harrison DG, Bohm M, Meinertz T, Munzel T. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation. 1999;99:2027-2033.
12. Quinn MJF, Williams GH. Regulation of aldosterone secretion. Ann Rev Physiol. 1988;50:409-426.
13. Schiffrin EL, Gutkowska J, Genest J. Effect of angiotensin II and deoxycorticosterone infusion on vascular angiotensin II receptors in rats. Am J Physiol. 1984;246:H608-H614.
14. Schiffrin EL, Franks DJ, Gutkowska J. Effect of aldosterone on vascular angiotensin II receptors in the rat. Can J Physiol Pharmacol. 1985;63:1522-1527.
15. Ullian ME, Schelling JR, Linas SL. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension. 1992;20:67-73.
16. Ullian ME, Walsh LG, Morinelli TA. Potentiation of angiotensin II action by corticosteroids in vascular tissue. Cardiovasc Res. 1996;32:266-273.
17. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H. Vascular aldosterone: biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem. 1994;289:24316-24320.
18. MacLeod AB, Vasdev S, Smeda JS. The role of blood pressure and aldosterone in the production of hemorrhagic stroke in captopril-treated hypertensive rats. Stroke. 1997;28:1821-1829.
19. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT. Mineralcorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension. 1998;31:451-458.
20. Fiebeler A, Schmidt F, Müller DN, Park JK, Dechend R, Bieringer M, Shagdarsuren E, Breu V, Haller H, Luft FC. Mineralcorticoid receptor affects AP-1 and nuclear factor-kB activation in angiotensin II-induced cardiac injury. Hypertension. 2001;37:787-793.
21. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation. 2000;101:1653-1659.
22. Heagerty AM, Aalkjaer C, Bund SJ, Korsgaard N, Mulvany MJ. Small artery structure in hypertension: dual process of remodeling and growth. Hypertension. 1993;21:391-397.
23. Chen X, Touyz RM, Park JB, Schiffrin EL. Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension. 2001;38:606-611.
24. Schisterman EF, Faraggi D, Browne R, Freudenheim J, Dorn J, Muti P, Armstrong D, Reiser B, Trevisan M. TBARS and cardiovascular disease in a population-based sample. J Cardiovasc Risk. 2001;8:219-225.
25. Schiffrin EL, Thorne FS, Genest J. Vascular angiotensin II receptors in renal and DOCA-salt hypertensive rats. Hypertension. 1983;5:V16-V21.
26. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension. 2001;38:581-587.
27. Touyz RM, He G, El Mabrouk M, Schiffrin EL. p38 Map kinase regulates vascular smooth muscle cell collagen synthesis by angiotensin II in SHR but not in WKY. Hypertension. 2001;37:574-580.
28. 2 angiotensin receptors in apoptosis in rat blood vessels. Hypertension. 1999;34:617-624.
29. Griffin SA, Brown WCB, Macpherson F, McGrath JC, Wilson VG, Korsgaard N, Mulvany MJ, Lever AF. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension. 1991;17:626-635.
30. Su EJ, Lombardi DM, Siegal J, Schwartz SM. Angiotensin II induces vascular smooth muscle cell replication independent of blood pressure. Hypertension. 1998;31:1331-1337.
31. Parker SB, Wade SS, Prewitt RL. Pressure mediates angiotensin II induced arterial hypertrophy and PDGF-A expression. Hypertension. 1998;32:452-458.
32. Takeda Y, Miyamori I, Yoneda T, Hatakeyama H, Inaba S, Furukawa K, Mabushi H, Takeda R. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab. 1996;81:2797-2800.
33. Rizzoni D, Porteri E, Castellano M, Bettoni G, Muiesan ML, Muiesan P, Giulini SM, Agabiti-Rosei E. Vascular hypertrophy and remodeling in secondary hypertension. Hypertension. 1996;28:785-790.
34. A receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension. 2001;37:1444-1449.
35. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594-597.
36. Barton M, d'Uscio LV, Shaw S, Meyer P, Moreau P, Lüscher TF. ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension. 1998;31:499-504.
37. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension. 1993;21:929-933.
38. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers Q IV, Taylor WR, Harrison DG, de Leon H, Wilcox JN, Griendling KK. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res. 1997;80:45-51.
39. Munzel T, Kurz S, Rajagopalan S, Thoenes M, Berrington WR, Thompson JA, Harrison DG. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest. 1996;98:1465-1470.
40. Schiffrin EL. Vascular smooth muscle growth and extracellular matrix deposition: is there a role for the sympathetic nervous system? J Hypertens. 2002;20:179-181.
41. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.